How Intrasurgical OCT can Impact the Surgical Approach to Membrane Peeling

OCTWhen treating patients with vitreomacular traction (VMT), peeling of the inner limiting membrane (ILM) or an epiretinal membrane (ERM) is often indicated. Successful outcomes depend on precise surgical maneuvers as well as the surgeon’s experience in order to assess whether the entire membrane has been removed, as this is crucial for successful release of traction. Having as much visual information as possible helps the surgeon confidently perform membrane peeling. It also supports identification of residual membranes, and examination of the retinal morphology immediately following the procedure for complications such as macular holes, sub-retinal edema or residual traction. High-resolution cross-sectional imaging provided by intrasurgical optical coherence tomography (OCT) can provide vital anatomic information to surgeons during retinal procedures, helping to guide surgical decision-making.

Showing different steps of removing an ERM to resolve VMT, the following videos captured with EnFocus intrasurgical Optical Coherence Tomography demonstrate how visualization of the membrane can impact the surgical process of membrane peeling. Imaging with EnFocus intrasurgical OCT supports identification of an epiretinal membrane (ERM) causing vitreomacular traction (VMT) and helps guide intrasurgical decision-making during membrane peeling:


Vitreomacular traction (VMT) and Epiretinal membrane (ERM)

Pre-operative retinal scan shows vitreomacular traction (VMT) and Epiretinal membrane (ERM).

 OCT reveals residual membrane

After ERM peeling, OCT reveals residual membrane creating longitudinal traction.

OCT confirms that the membrane creating longitudinal traction has been severed

After further surgical intervention, OCT confirms that the membrane creating longitudinal traction has been severed and no macular hole created. The surgeon decides air exchange is not required, sparing the patient from prone positioning.


Contact DB Surgical for More Information.

Republished from Leica Microsystems.

 

Leica Microsystems Receives Award as Technology Leader

Wetzlar, Germany. The research and consulting company Frost & Sullivan has recognized Leica Microsystems’ newly acquired Optical Coherence Tomography (OCT) company Bioptigen of Morrisville, North Carolina, USA, as a technology leader and pioneer of the North American ophthalmic imaging industry. The Frost & Sullivan Award ceremony took place January 13, 2016 in San Diego, USA.

In their appraisal, Frost & Sullivan calls attention to the value represented in Bioptigen’s OCT solutions: “Frost & Sullivan recognizes the enormous value addition Bioptigen’s Envisu Spectral Domain (SD)-OCT platform brings to ophthalmic imaging.”

Particularly emphasized are the highly customizable imaging solutions for pre-clinical and clinical applications. Bioptigen is offering hand-held OCT imaging capabilities bringing OCT directly to the patient. Quick and sensitive real-time OCT imaging minimizes the challenges of comprehensive eye examinations with supine and non-compliant patients, such as infants and children. Bioptigen offers the world’s only hand-held OCT solution approved by the FDA for use as an aid in the diagnosis of physiological and pathologic conditions of the eye.

Markus Lusser, President of Leica Microsystems, expressed his pride at the award: “Leica Microsystems is honored that Bioptigen has been selected for the Frost & Sullivan Award. It is tangible proof of the Bioptigen team’s dedication to creativity, innovation, and the constant exploration of growth potential in the vision healthcare market.”

Bioptigen develops and manufactures innovative OCT systems and software and provides products for clinical as well as translational research applications globally. Bioptigen currently markets the Envisu OCT for pediatric ophthalmic imaging applications, and a family of OCT imaging products for vision science research. Notably, in December 2015, the company received FDA clearance for EnFocus, an innovative OCT ophthalmic imaging solution to upgrade surgical microscopes with intrasurgical OCT capabilities directly integrated in the light path of the microscope. Bioptigen was acquired by Leica Microsystems in 2015.



 

 


Contact DB Surgical for more information.

Republished from Leica Microsystems